USSTOCK.TODAY
Market Closed
Log in Sign up

BioNTech and Moderna Compete to Expand Beyond COVID-19 Vaccines into Cancer Treatment Market

The Motley Fool +1 · ·by G4L

MRNA Moderna Inc
$269.00 +5.83%
View chart & analysis →
BNTX BNTX 0.00% BMY 0.00%
  1. 1BioNTech is collaborating with Bristol Myers Squibb and Roche to develop cancer treatments and vaccines.
  2. 2Moderna has raised its annual revenue growth outlook to 15%–25%.
  3. 3BioNTech recorded a net loss of approximately $1.3 billion for fiscal year 2025.

So what's the key point?

BioNTech is teaming up with other companies to create cancer treatments and vaccines. In this process, a net loss of about $1.3 billion is expected for 2025.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Moderna achieves profitability with $1.4 billion in third-quarter revenue The Motley Fool · yesterdayModerna turns profitable in Q3 with $1.31 billion in revenue Investing.com · 2d agoModerna shares hit multi-year high following Q3 earnings release Schaeffer's Research · 2d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news